Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTZymeworks Inc.'s latest supported as-filed period reports revenue of $4.6M, 90.6% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -696.03% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -90.58% · CORE
Level · gp.fundamentals.operating_margin
Raw value -918.95% · CORE
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 246.93% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +82.6% from the comparable as-filed period.
Net income changed -2043.0% from the comparable as-filed period.
Operating income changed -6158.2% from the comparable as-filed period.
Operating margin changed -91757 basis points from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
ZYME · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001937653-26-000051SEC ↗10-QAug 6, 2026Period Jun 30, 20260001937653-26-000047SEC ↗8-KAug 6, 2026Period Aug 6, 20260001937653-26-000046SEC ↗4Jul 6, 2026Period Jul 6, 20260002104446-26-000009SEC ↗8-KJun 29, 2026Period Jun 28, 20260001193125-26-286829SEC ↗4May 15, 2026Period May 13, 20260001193125-26-227140SEC ↗8-KMay 14, 2026Period May 14, 20260001193125-26-224161SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 6, 2026Filed Jul 6, 2026 | Hollywood MarkEVP & Chief Operating Officer | Grant Or AwardDirect | 939 | $22 | $20,865 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Revenue changed -90.6% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001937653-26-000034